Should you buy Gilead Sciences stock now?
Yes, the technical signal for Gilead Sciences is currently BUY. Gilead Sciences trades at $129.84 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.685 with falling momentum (signal: 0.721); RSI is at 51.0 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $157.15 points to 21.0% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Gilead Sciences stock?
The average analyst price target for Gilead Sciences is $157.15. The current price is $129.84, which gives an upside of 21.0%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $141.44 and $172.87.
Is Gilead Sciences a dividend stock?
Yes, Gilead Sciences is a dividend stock with a dividend yield of 2.43%. The latest dividend was $0.82 per share. The latest ex-dividend date (traded without the dividend) was 6/15/2026. The payout ratio is 38.5%, which is considered sustainable. The next dividend payment is scheduled for 6/29/2026.
When does Gilead Sciences pay a dividend in 2026?
Gilead Sciences pays its next dividend on 6/29/2026. The latest dividend was $0.82 per share with an ex-dividend date of 6/15/2026. The dividend yield is 2.43%. The payout ratio of 38.5% points to a sustainable dividend with room to grow.
What is the risk of Gilead Sciences stock?
Gilead Sciences is rated as a stock with moderately low risk. the annual standard deviation is 27.2%, which classifies the stock as moderately low risk.
Is Gilead Sciences overvalued?
No, Gilead Sciences is considered undervalued based on the analyst price target (21.0% upside). Gilead Sciences has the following valuation ratios: a P/E ratio of 18.4 (moderately valued), a P/S ratio of 5.6, a P/B ratio of 6.9. The analyst price target suggests that the stock is undervalued by 21.0%.
Is Gilead Sciences overbought?
No, Gilead Sciences is not overbought. RSI is at 51.0 (neutral zone). The technical indicators show: RSI is at 51.0 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.6% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next Gilead Sciences earnings report?
The date of the next earnings report for Gilead Sciences has not been published yet. Check the company's investor calendar for updates.
Is Gilead Sciences shorted?
Yes, Gilead Sciences is shorted with 2.0% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Gilead Sciences stock?
Yes, insiders are net buyers of Gilead Sciences – they are buying more shares than they are selling. Over the last 3 months, insiders have made 1 purchases and 14 sales. On a net basis, 1,719,402 $ worth of shares were bought. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 602,750 $ sold. Active buyers include GILEAD SCIENCES, INC.. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Gilead Sciences a good stock?
Based on our total score, Gilead Sciences is rated as a good stock with a total score of 66 out of 100. The stock scores above average on value, quality and momentum – it is among the top 34% in our database. The score is made up of Value: 52/100, Quality: 90/100, Momentum: 57/100. In addition: analysts see 21.0% upside to the price target; a dividend of 2.43%; technical signal: Buy. Whether Gilead Sciences is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Gilead Sciences stock?
The outlook for Gilead Sciences based on current data: the average analyst price target is $157.15 (+21.0%); the P/E ratio is 18.4 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Gilead Sciences stock moving?
Gilead Sciences is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Gilead Sciences go?
The average analyst price target for Gilead Sciences is $157.15, which corresponds to a potential gain of 21.0% from the current price of $129.84. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Gilead Sciences fall?
We lack enough history to give a specific floor for Gilead Sciences. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Gilead Sciences do?
Gilead Sciences er et biofarmaceutisk selskab, som udvikler og sælger medicin til områder med stort medicinsk behov. De tjener primært penge på behandlinger mod HIV/AIDS, leverlidelser og kræft. Gilead er især kendt for deres HIV-midler som Biktarvy og Descovy. De leverer også... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - General industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Gilead Sciences as an investment.
Did Gilead Sciences raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Gilead Sciences. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Gilead Sciences making money or losing money?
Yes, Gilead Sciences is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 31.0% — which is excellent. The operating margin (profit before interest and taxes) is 39.3%. At a P/E ratio of 18.4, you currently pay 18.4 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Gilead Sciences go bankrupt?
The bankruptcy risk of Gilead Sciences is rated as moderate. Altman Z2 (a model for assessing financial distress) is 2.13 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 206% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Gilead Sciences have a lot of debt?
Yes, Gilead Sciences has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 206%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
